Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report

Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab...

Full description

Saved in:
Bibliographic Details
Published inIntractable & Rare Diseases Research Vol. 10; no. 2; pp. 122 - 125
Main Authors Gupta, Sonia, Rakhra, Amandeep, Thallapally, Vinay, Nahas, Joseph
Format Journal Article
LanguageEnglish
Published Japan International Research and Cooperation Association for Bio & Socio-Sciences Advancement 01.05.2021
Subjects
anti-HMGCR
Case Report
immune-mediated necrotizing myopathy
immunosuppressants
rituximab
anti-HMGCR
immune-mediated necrotizing myopathy
immunosuppressants
rituximab
Online AccessGet full text

Cover

More Information
Summary:Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab is more limited in this type of myopathy. Reported here is a case of a patient who responded well to rituximab (RTX) after the standard immunosuppressants had failed. This case illustrates the importance of further studies to evaluate the role of RTX in anti-HMGCR myopathy.
ISSN:2186-3644
2186-361X
DOI:10.5582/irdr.2020.03144